Monday, June 8, 2020

Teva Pharmaceuticals Vacancy for Regulatory Affairs Associate I MSc / Bpharm


Teva Pharmaceuticals Vacancy for Regulatory Affairs Associate I MSc / Bpharm


Company Info

Teva is a global pharmaceutical leader and the world's largest generic medicines producer, committed to improving health and increasing access to quality health solutions worldwide. Our employees are at the core of our success, with colleagues in over 80 countries delivering the world's largest medicine cabinet to 200 million people every day. We offer a uniquely diverse portfolio of products and solutions for patients and we've built a promising pipeline centered around our core therapeutic areas.  We are continually developing patient-centric solutions and significantly growing both our generic and specialty medicines business through investment in research and development, marketing, business development and innovation. This is how we improve health and enable people to live better, healthier lives. Join us on our journey of growth!

Job Description

They will be responsible for Metrics and Reporting mainly for EU, but ad hoc Globally and for supporting GRA Compliance.

Work with other members of staff for reporting EU Gx & Specialties metrics.

Provide ad hoc global or regional reports, as required

GRAP/AQUA data entry

Retrieval and analysis of data from GRAP and AQUA

EU submission fee calculations

Assist with managing GRA’s procedures and learning systems for SOPs & Work Instructions, including processing through established DMS and LMS and monitoring of periodic reviews.

The candidate will be expected to work within GRA, liaising with other business units (eg R&D, portfolio, RA etc) to ensure that all data is compliant.

They need to be familiar with the IT systems the company uses in order to retrieve the data efficiently and accurately.

Function

Regulatory Affairs

Qualifications

1-2 Yrs MSc / BPharm with exposure to  metrics and reporting mainly for EU.

TO APPLY CLICK HERE

FOR MORE JOB UPDATES




JOIN IN GROUP FOR DAILY UPDATES


No comments:

Post a Comment